Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Trillium Therapeutics Inc. (TRIL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
11/19/2021 |
4
| Walker Paul Edward (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 5,736,363 shares
@ $0 Disposed/sold 850,000 options to buy
@ $0.96, valued at
$816k
Disposed/sold 6,750,000 options to buy
@ $0 Disposed/sold 5,400,000 options to buy
@ $0.96, valued at
$5.2M
Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
|
|
11/19/2021 |
4
| Pucci Paolo (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 67,000 options to buy
@ $15.5, valued at
$1M
|
|
11/19/2021 |
4
| Myers Scott Dunseth (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 67,000 options to buy
@ $9.51, valued at
$637.2k
|
|
11/19/2021 |
4
| Harrison Rosemary (See Remarks) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 75 shares
@ $0 Disposed/sold 180,000 options to buy
@ $14.11, valued at
$2.5M
|
|
11/19/2021 |
4
| BESHAR LUKE M (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
Disposed/sold 6,666 options to buy
@ $0 Disposed/sold 547,656 restricted stock units
@ $0 |
|
11/19/2021 |
4
| Parsons James T. (CFO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 180,000 options to buy
@ $12.03, valued at
$2.2M
Disposed/sold 94,792 options to buy
@ $0 Disposed/sold 59,896 options to buy
@ $0 Disposed/sold 5,761 options to buy
@ $0 Disposed/sold 36,204 options to buy
@ $0 Disposed/sold 24,390 options to buy
@ $0 Disposed/sold 30,171 options to buy
@ $0 |
|
11/19/2021 |
4
| Kamarck Michael E. (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 67,000 options to buy
@ $14.77, valued at
$989.6k
|
|
11/19/2021 |
4
| Looker Benjamin (General Counsel) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 190,000 options to buy
@ $9.51, valued at
$1.8M
|
|
11/19/2021 |
4
| MACKEY CATHERINE J (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 67,000 options to buy
@ $9.7, valued at
$649.9k
|
|
11/19/2021 |
4
| Bruns Ingmar (Chief Medical Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 400,000 options to buy
@ $14.11, valued at
$5.6M
|
|
11/19/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 38,808 options to buy
@ $0 Disposed/sold 4,574 options to buy
@ $0 Disposed/sold 49,480 options to buy
@ $0 Disposed/sold 83,960 options to buy
@ $0 Disposed/sold 140,000 options to buy
@ $12.03, valued at
$1.7M
|
|
11/19/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 102,083 options to buy
@ $0 Disposed/sold 58,333 options to buy
@ $0 Disposed/sold 5,260 options to buy
@ $0 Disposed/sold 23,473 options to buy
@ $0 Disposed/sold 29,073 options to buy
@ $0 Disposed/sold 250,000 options to buy
@ $12.03, valued at
$3M
|
|
11/19/2021 |
4
| TAYTON-MARTIN HELEN KATRINA (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
Disposed/sold 498,294 restricted stock units
@ $0 |
|
11/19/2021 |
4
| Skvarka Jan (President and CEO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Disposed/sold 197,000 options to buy
@ $0 Disposed/sold 1,162,500 options to buy
@ $0 Disposed/sold 600,000 options to buy
@ $12.03, valued at
$7.2M
|
|
07/09/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.3039, valued at
$1.1k
Sold 3,646 shares
@ $9, valued at
$32.8k
Exercised 3,646 options to buy
@ $0 |
|
07/02/2021 |
4
| MACKEY CATHERINE J (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Granted 67,000 options to buy
@ $9.7, valued at
$649.9k
|
|
06/09/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.315, valued at
$1.1k
Sold 3,646 shares
@ $8.27, valued at
$30.2k
Exercised 3,646 options to buy
@ $0 |
|
05/13/2021 |
4
| Skvarka Jan (President and CEO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 87,500 shares
@ $0.4462, valued at
$39k
Exercised 19,198 shares
@ $0.314, valued at
$6k
Sold 106,698 shares
@ $9.2017, valued at
$981.8k
Exercised 23,802 shares
@ $0.314, valued at
$7.5k
Sold 23,802 shares
@ $9.2379, valued at
$219.9k
Exercised 87,500 options to buy
@ $0 Exercised 19,198 options to buy
@ $0 Exercised 23,802 options to buy
@ $0 |
|
05/11/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.313, valued at
$1.1k
Sold 3,646 shares
@ $9.3, valued at
$33.9k
Exercised 3,646 options to buy
@ $0 |
|
05/05/2021 |
4
| Looker Benjamin (General Counsel) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Granted 190,000 options to buy
@ $9.51, valued at
$1.8M
|
|
05/05/2021 |
4
| Myers Scott Dunseth (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Granted 67,000 options to buy
@ $9.51, valued at
$637.2k
|
|
04/09/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.3012, valued at
$1.1k
Sold 3,646 shares
@ $10.82, valued at
$39.4k
Exercised 3,646 options to buy
@ $0 |
|
04/09/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 2,708 shares
@ $0.3022, valued at
$818.4 Exercised 2,604 shares
@ $3.3638, valued at
$8.8k
Sold 5,312 shares
@ $11.09, valued at
$58.9k
Exercised 2,708 options to buy
@ $0 Exercised 2,604 options to buy
@ $0 |
|
03/15/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 2,917 shares
@ $3.3924, valued at
$9.9k
Sold 2,917 shares
@ $11.97, valued at
$34.9k
Exercised 2,917 options to buy
@ $0 |
|
03/12/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 2,708 shares
@ $0.3012, valued at
$815.6 Exercised 2,604 shares
@ $3.3524, valued at
$8.7k
Sold 5,312 shares
@ $11.08, valued at
$58.9k
Exercised 2,708 options to buy
@ $0 Exercised 2,604 options to buy
@ $0 |
|
03/10/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.2999, valued at
$1.1k
Sold 3,646 shares
@ $10.11, valued at
$36.9k
Exercised 3,646 options to buy
@ $0 |
|
02/10/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 2,708 shares
@ $0.2977, valued at
$806.2 Exercised 2,604 shares
@ $3.3137, valued at
$8.6k
Sold 5,312 shares
@ $12.65, valued at
$67.2k
Exercised 508 shares
@ $9.6213, valued at
$4.9k
Sold 508 shares
@ $14.174, valued at
$7.2k
Exercised 2,708 options to buy
@ $0 Exercised 2,604 options to buy
@ $0 Exercised 508 options to buy
@ $0 |
|
02/10/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 3,646 shares
@ $0.2977, valued at
$1.1k
Exercised 2,917 shares
@ $3.3137, valued at
$9.7k
Sold 6,563 shares
@ $12.65, valued at
$83k
Exercised 584 shares
@ $9.6213, valued at
$5.6k
Sold 584 shares
@ $14.124, valued at
$8.2k
Exercised 3,646 options to buy
@ $0 Exercised 2,917 options to buy
@ $0 Exercised 584 options to buy
@ $0 |
|
01/15/2021 |
4
| Skvarka Jan (President and CEO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 5,419 shares
@ $0.4248, valued at
$2.3k
Sold 5,419 shares
@ $15.0411, valued at
$81.5k
Exercised 19,581 shares
@ $0.4275, valued at
$8.4k
Sold 19,581 shares
@ $15.0288, valued at
$294.3k
Exercised 5,419 options to buy
@ $0 Exercised 19,581 options to buy
@ $0 |
|
01/13/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 584 shares
@ $9.5671, valued at
$5.6k
Sold 584 shares
@ $15.2032, valued at
$8.9k
Exercised 584 options to buy
@ $0 |
|
01/13/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 508 shares
@ $9.5671, valued at
$4.9k
Sold 508 shares
@ $15.2073, valued at
$7.7k
Exercised 508 options to buy
@ $0 |
|
01/12/2021 |
4
| Parsons James T. (CFO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 8,505 shares
@ $7.2447, valued at
$61.6k
Sold 8,505 shares
@ $15.7873, valued at
$134.3k
Exercised 8,505 options to buy
@ $0 |
|
01/12/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 5,600 shares
@ $11.0087, valued at
$61.6k
Sold 5,600 shares
@ $15.817, valued at
$88.6k
Exercised 2,917 shares
@ $3.331, valued at
$9.7k
Sold 2,917 shares
@ $15.5058, valued at
$45.2k
Exercised 5,600 options to buy
@ $0 Exercised 2,917 options to buy
@ $0 |
|
01/12/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns:
| Exercised 2,604 shares
@ $3.331, valued at
$8.7k
Sold 2,604 shares
@ $15.501, valued at
$40.4k
Exercised 2,604 options to buy
@ $0 |
|
|
|
|